A prospective, observational study to evaluate effectiveness and safety of fixed dose combination of Indacaterol maleate 110 mcg and Glycopyrronium bromide 50 mcg in stable Chronic Obstructive Pulmonary Disease (COPD) patients
Phase 4
Completed
- Conditions
- Health Condition 1: null- Chronic Obstructive Pulmonary Disease
- Registration Number
- CTRI/2016/11/007460
- Lead Sponsor
- ovartis Healthcare private limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. COPD patients prescribed with FDC of Indacaterol maleate 110 mcg + Glycopyrronium bromide 50 mcg as per discretion of treating physician and as per product prescribing information.
2. Patients willing to participate in the study by providing written informed consent.
Exclusion Criteria
1. Contraindication as per PI
2. Patients simultaneously participating in other studies or use of other investigational drug at the time of enrollment or 5 times the half life of the investigational product prior to visit 1.
Pregnant women should not be included except if, in the opinion of the investigator, the expected benefit outweighs the potential risk to the fetus (please see Section 11 for further information).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method